Aspen Neuroscience Announces $147.5 Million Series B Financing, led by GV, LYFE Capital and Revelation Partners

Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease, announced the close of its Series B funding round of $147.5 million.

Aspen Neuroscience Announces $147.5 Million Series B Financing, led by GV, LYFE Capital and Revelation Partners Read More »

Singapore’s Neuron Mobility Triples its Global Operations and Raises US$43.5 Million to Fuel Rapid International Expansion and Accelerate Tech Leadership

Neuron Mobility, Canada’s fastest-growing shared e-scooter and e-bike operator, announces it has successfully raised US$43.5 million in Series B funding. This follows 19 months of significant growth and brings the company’s total funding to US$77.7 million.

Singapore’s Neuron Mobility Triples its Global Operations and Raises US$43.5 Million to Fuel Rapid International Expansion and Accelerate Tech Leadership Read More »

RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity

RVAC Medicines, an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group, announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million.

RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity Read More »